# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4767464 | B | Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 50 uM incubated for 60 mins in presence of ATP by FRET based Z'-LYTE assay | Homo sapiens | 14 | assay format | Scientific Literature | ||
2. | ALA4767465 | B | Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 5 uM incubated for 60 mins in presence of ATP by FRET based Z'-LYTE assay | Homo sapiens | 14 | assay format | Scientific Literature | ||
3. | ALA4767466 | B | Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 0.5 uM incubated for 60 mins in presence of ATP by FRET based Z'-LYTE assay | Homo sapiens | 14 | assay format | Scientific Literature | ||
4. | ALA4767467 | P | Chemical stability of the compound in pH 7.4 PBS buffer assessed as compound remaining measured after 2 hrs by HPLC analysis | 12 | small-molecule physicochemical format | Scientific Literature | |||
5. | ALA4767468 | U | Chemical stability of the compound in pH 1.2 simulated gastric fluid buffer assessed as compound remaining measured after 2 hrs by HPLC analysis | 12 | small-molecule physicochemical format | Scientific Literature | |||
6. | ALA4767469 | U | Chemical stability of the compound in pH 6.8 simulated intestinal fluid assessed as compound remaining measured after 2 hrs by HPLC analysis | 12 | small-molecule physicochemical format | Scientific Literature | |||
7. | ALA4767470 | A | Stability of the compound in human plasma assessed as compound remaining measured within 120 mins at 37 degC by HPLC analysis | Homo sapiens | 13 | cell-free format | Scientific Literature | ||
8. | ALA4767471 | A | Prodrug conversion in human plasma assessed as release of active metabolite (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride measured within 120 mins at 37 degC by HPLC analysis | Homo sapiens | 12 | cell-free format | Scientific Literature | ||
9. | ALA4767472 | A | Stability of the compound in rat liver S9 fraction assessed as compound remaining measured after 60 mins at 37 degC by LC-MS/MS analysis | Rattus norvegicus | 13 | subcellular format | Scientific Literature | ||
10. | ALA4767473 | A | Prodrug conversion in rat liver S9 fraction assessed as release of active metabolite (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride measured after 60 mins at 37 degC by LC-MS/MS analysis | Rattus norvegicus | 12 | subcellular format | Scientific Literature | ||
11. | ALA4767496 | A | AUC in Wistar rat assessed as (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride at 14.18 mg/kg, po measured upto 24 hrs by LC/MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
12. | ALA4767497 | A | AUC (0 to infinity) in Wistar rat assessed as (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride at 14.18 mg/kg, po measured upto 24 hrs by LC/MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
13. | ALA4767498 | A | Half life in Wistar rat assessed as (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride at 14.18 mg/kg, po measured upto 24 hrs by LC/MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
14. | ALA4767499 | A | Tmax in Wistar rat assessed as (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride at 14.18 mg/kg, po measured upto 24 hrs by LC/MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
15. | ALA4767500 | A | Cmax in Wistar rat assessed as (R)-(6-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone hydrochloride at 14.18 mg/kg, po measured upto 24 hrs by LC/MS/MS analysis | Rattus norvegicus | 1 | organism-based format | Scientific Literature |